Bryxta 400mg Injection (Bevacizumab)

Bryxta 400mg injection is a prescription-based targeted anticancer medicine used in the treatment of breast cancer, brain cancer, cervical cancer, kidney cancer, lung cancer, and colorectal cancer. The active ingredient of Bryxta is bevacizumab, which belongs to the drug class of vascular endothelial growth factor (VEGF) inhibitors. It works by acting against a protein known as Vascular Endothelial Growth Factors (VEGF) to control the growth and spread of the cancer cells. Bevacizumab injection is usually given in combination with another anticancer medicine as a part of combination therapy to increase the efficacy of the treatment.

The injection is administered as an intravenous infusion by a qualified doctor in a hospital or clinical setting. The doctor determines the dosage of the bevacizumab 400mg injection according to the type of cancer, treatment regimen, age, and overall health of the patient. It should not be self-administered. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include high blood pressure, tiredness, weakness, headache, loss of appetite, diarrhea, nausea, mouth sores, and joint or muscle pain. A few patients can undergo severe side effects, including severe bleeding, blood clots, gastrointestinal perforation, impaired wound healing, or kidney problems. Most of the bevacizumab 400mg injection side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

The medicine can impair wound healing, so it may need to be stopped before or after surgery, and pregnant patients or breastfeeding mothers should consult with their doctor before the treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Bevacizumab 400mg injection must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Colorectal Cancer

Bryxta 400mg Injection (Bevacizumab 400mg) is a target therapy-based medication. It is given in combination with other chemotherapeutic drugs to treat various types of cancers. It contains monoclonal antibody as its main active ingredient. Therefore, it causes multiple side effects. Immediately consult your doctor if side effects persist for a longer length of time.

Common Side Effects of Bryxta 400mg Injection:
● Constipation
● Reduced Appetite
● Headache
● Vomiting
● Sweating
● Fatigue
● Taste Change
● Body Ache
● High Blood Pressure
● Mouth Sore
● Proteinuria
● Risk of Infection
● Wound Healing Problem

Serious Side Effects of Bryxta 400mg Injection:
● Gastrointestinal Perforation
● Blood Clots
● Severe Bleeding
● Heart Problems
● Stroke
● Neurological Issues
● Posterior Reversible Encephalopathy Syndrome

The dosage of Bryxta 400mg Injection (Bevacizumab 400mg) depends on the cancer type, its stage, and the patient's overall health. Though the standard dosage range varies from 5 to 15 mg/kg body weight administered every 2-3 weeks. For an exact personalized dosage, visit your doctor for a consultation. Bryxta 400mg Injection is administered intravenously (in veins) by a doctor or a professional and experienced nurse. Do not self-administer the injection.

● Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2012). Bevacizumab: overview of the literature. Expert review of anticancer therapy, 12(5), 567-580.

● Ellis, L. M., & Kirkpatrick, P. (2005). Bevacizumab. Nature reviews Drug discovery, 4.
Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discovery, 3(5), 391-400.

● Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007). Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology, 114(5), 855-859.